No Data
Cathie Wood Sees $400B Opportunity In Biologics — How Have Her Bets Fared?
Tradepulse Power Inflow Alert: Eli Lilly & Company Climbs Over 22 Points After Alert
S&P 500, Dow Hit Records, Trump Tariffs to Cost Hundreds of Billions | Wall Street Today
Amgen's weight loss drug has a remarkable 20% reduction effect, but with high side effects, causing the stock price to plummet by 12.3% at one point!
Although the weight loss effect of amgen's MariTide drug met expectations, the high side effects, lower than eli lilly and co's Zepbound, and the trial results falling below Wall Street's high expectations, led to amgen's stock price plunging over 12.3% on Tuesday, far behind eli lilly and co and novo-nordisk a/s, which benefited from the Biden policy rise at the same time. In a one-year trial, MariTide helped non-diabetic patients lose up to 20% of their weight, comparable to the maximum dose effect of eli lilly's Zepbound. However, the side effects are significant, with about 11% of patients dropping out of the trial due to side effects, higher than eli lilly's 7%.
Stocks Mixed Ahead Of Fed Minutes, Mexican Peso Tumbles To Over 2-Year Lows On Tariffs Fears: What's Driving Markets Tuesday?
Twist Bioscience Analyst Ratings